Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates

J Glob Antimicrob Resist. 2017 Dec:11:154-155. doi: 10.1016/j.jgar.2017.10.016. Epub 2017 Oct 31.

Authors

Erik Skoglund¹, Kimberly R Ledesma², Todd M Lasco³, Vincent H Tam⁴

Affiliations

¹ University of Houston College of Pharmacy, Houston, TX, USA; CHI Baylor St Luke's Medical Center, Houston, TX, USA.
² University of Houston College of Pharmacy, Houston, TX, USA.
³ CHI Baylor St Luke's Medical Center, Houston, TX, USA.
⁴ University of Houston College of Pharmacy, Houston, TX, USA; CHI Baylor St Luke's Medical Center, Houston, TX, USA. Electronic address: vtam@uh.edu.

PMID: 29101084
DOI: 10.1016/j.jgar.2017.10.016

No abstract available

Publication types

Letter

MeSH terms

Bacteremia / drug therapy
Bacteremia / microbiology
Cephalosporins / pharmacology*
Drug Resistance, Bacterial / drug effects*
Humans
Immunocompromised Host
Intensive Care Units
Meropenem
Microbial Sensitivity Tests
Pseudomonas Infections / drug therapy
Pseudomonas Infections / microbiology
Pseudomonas aeruginosa / drug effects*
Pseudomonas aeruginosa / isolation & purification
Tazobactam / pharmacology*

Substances

Cephalosporins
ceftolozane, tazobactam drug combination
Meropenem
Tazobactam